

Supplementary Data 1. Alignment of *HSP83* coding sequences

The ten copies of *HSP83* in TriTrypDb (Tb927.10.10890, 10900, 10910, 10920, 10930, 10940, 10950, 10960, 10970, 10980) were aligned using Clustal O (1.2.1). Synonymous variations are highlighted in *green*, nonsynonymous variations are in *yellow*, RNAi sequence is in *red*.

CLUSTAL O(1.2.1) multiple sequence alignment

```
Tb...10930      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10970      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10980      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10960      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10950      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10940      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10910      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10920      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10900      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
Tb...10890      ATGACGGAGACATTTCGCATTCCAGGCTGAAATCAATCAGCTAATGTC CCTTATTATTAAT      60
*****

Tb...10930      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10970      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10980      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10960      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10950      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10940      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10910      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10920      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10900      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
Tb...10890      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG      120
*****

Tb...10930      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10970      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10980      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10960      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10950      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10940      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10910      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10920      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10900      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
Tb...10890      TGGCAGAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT      180
*****

Tb...10930      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10970      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10980      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10960      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10950      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10940      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10910      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10920      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10900      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
Tb...10890      TTGGCGCATTTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGCC      240
*****

Tb...10930      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC      300
Tb...10970      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC      300
Tb...10980      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC      300
Tb...10960      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC      300
```

Tb...10950	ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC	300
Tb...10940	ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC	300
Tb...10910	ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC	300
Tb...10920	ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC	300
Tb...10900	ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC	300
Tb...10890	ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC *****	300
Tb...10930	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10970	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10980	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10960	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10950	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10940	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10910	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10920	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10900	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC	360
Tb...10890	AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC *****	360
Tb...10930	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10970	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10980	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10960	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10950	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10940	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10910	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10920	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10900	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC	420
Tb...10890	GTCGGATTTTACTCTGCCTACCTTGTGCGCAGACCCGTAACCGTTGTGTCGAAGAACAAC *****	420
Tb...10930	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10970	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10980	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10960	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10950	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10940	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10910	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10920	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10900	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG	480
Tb...10890	GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG *****	480
Tb...10930	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10970	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10980	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10960	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10950	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10940	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10910	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10920	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10900	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG	540
Tb...10890	CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG *****	540
Tb...10930	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10970	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10980	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10960	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10950	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10940	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10910	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10920	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10900	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC	600
Tb...10890	GAATACCTGGAGGAGCGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC *****	600
Tb...10930	TACGACATCGAGTTAATGGTGGAGAACCACCTGAGAAGGAGGTGACAGATGAAGACGAA	660
Tb...10970	TACGACATCGAGTTAATGGTGGAGAACCACCTGAGAAGGAGGTGACAGATGAAGACGAA	660
Tb...10980	TACGACATCGAGTTAATGGTGGAGAACCACCTGAGAAGGAGGTGACAGATGAAGACGAA	660


Tb...10930	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10970	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10980	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10960	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10950	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10940	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10910	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10920	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10900	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100
Tb...10890	GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG	2100

Tb...10930	GAGGAAGTGGACTGA	2115
Tb...10970	GAGGAAGTGGACTGA	2115
Tb...10980	GAGGAAGTGGACTGA	2115
Tb...10960	GAGGAAGTGGACTGA	2115
Tb...10950	GAGGAAGTGGACTGA	2115
Tb...10940	GAGGAAGTGGACTGA	2115
Tb...10910	GAGGAAGTGGACTGA	2115
Tb...10920	GAGGAAGTGGACTGA	2115
Tb...10900	GAGGAAGTGGACTGA	2115
Tb...10890	GAGGAAGTGGACTGA	2115


Supplementary Table 1. Primers used in this study

Name	Purpose	Sequence ^a
MX-F	Maxicircle probe for Southern blots	CTAACATACCCACATAAGACAG
MX-R		ACACGACTCAATCAAAGCC
H83Xb-F	Incorporating restriction sites (Xb – XbaI, Nd – NdeI) on RNAi sequence for <i>HSP83</i>	CCCCTCTAGATATTGTGAAGAAGGCCCTGG
H83Nd-R		CCCCCATATGCTCTTTCATTGCCTTGCACA
H83Xh-F	Incorporating restriction sites (Xh – XhoI, As – AscI) on RNAi sequence for <i>HSP83</i>	CTCTCTCGAGTATTGTGAAGAAGGCCCTGG
H83As-R		CTTTGGCGCGCCCTTTCATTGCCTTGCACA
H84Xb-F	Incorporating restriction sites (Xb – XbaI, Nd – NdeI) on RNAi sequence for <i>HSP84</i>	CCCCTCTAGAGAGCTCTCCTTTTGCACACC
H84Nd-R		CCCCCATATGTGTGAACCTGGTCGGTACAA
H84Xh-F	Incorporating restriction sites (Xh – XhoI, As – AscI) on RNAi sequence for <i>HSP84</i>	CTTCCTCGAGAGCTCTCCTTTTGCACACC
H84As-R		GTATGGCGCGCCTGTGAACCTGGTCGGTACAA
H84Kp-F	Incorporating restriction sites (Kp – KpnI, Xh – XhoI) on terminal 400 bp of <i>HSP84</i>	CTATGGTACCCGTTGGCGTCGTCAAATC
H84Xh-R		CTTACTCGAGCTTATCGGCAGTGGGCTCCT
3UH84Bm-F	Incorporating restriction sites (Bm – BamHI, Sc – SacI) on 400 bp of 3'UTR of <i>HSP84</i>	CATTGGATCCGTGCAGAGTAAACATTTTTTC
3UH84Sc-R		CAATGAGCTCCAACGCACAGTAAAGGGTAT
H83m-F	<i>HSP83</i> probe for mRNA	CCAGAGTCTGACGAACCAGTC
H83m-R	northern blots	CCAGGTATTCCTGCTGGTCT
H84m-F	<i>HSP84</i> probe for mRNA	CTAAAGGGCAATGCAGGGGA
H84m-R	northern blots	CCGGCTGTACACCTTGACAT


^aRestriction sites underlined



Supplementary Figure 1. 17-AAG treatment halts trypanosome growth followed by a gradual decline in cell number. 2×10^5 Cells were treated with either DMSO or 100 nM 17-AAG and incubated at 37°C. Aliquots were taken across 48 h and live cells counted by hemocytometer and microscopy. Data are from 8 independent growth curves, geometric $M \pm SD$, $n = 3-8$ for each point.




Supplementary Figure 2. Abnormalities in kinetoplast segregation and cleavage furrow ingression after treatment with an Hsp90 inhibitor. Cells treated with 100 nM 17-AAG were harvested at indicated intervals, stained with DAPI, examined by fluorescence microscopy, and 2N cells were scored for presence of a visible cleavage furrow but normal kinetoplasts (*blue*, CF), no cleavage furrow but kinetoplasts not normally separated (*red*, Kns), or presence of both abnormalities (*purple*, CF + Kns). Values are $M \pm SD$; >175 2N cells observed at each time point.




Supplementary Figure 3. 17-AAG treatment leads to changes in free minicircle topology and in the cell content of mini- and maxicircle DNA. (A) Southern blot analysis of free minicircles isolated from trypanosomes treated for short periods with 100 nM 17-AAG. *Lane 1*, DNA from untreated cells; *Lanes 2-8*, increasing duration of 100 nM 17-AAG, as indicated (*bold*, top of lanes). (B) Southern blot analysis of free minicircles isolated from trypanosome lysates treated with or without proteinase K ($\pm PK$) prior to electrophoresis. *Lanes 1 and 2*, DNA from trypanosomes treated with topoisomerase II poison etoposide; *Lanes 3-9*, DNA from cells treated with 100 nM 17-AAG. Without protease digestion the linear forms are selectively lost from analysis, indicating their covalent linkage to topoisomerase protein [1]. *O*, Oligomers of two or more interlocked circles; *T*, theta structures; *N/G*, mature nicked, or gapped daughters; *L*, Linear, *N*, immature nicked daughters; *CC*, covalently closed template circles. (C) Southern blot analysis of free maxicircles (0.6% gel). *Lane 1*, BamHI-linearized maxicircle marker; *Lane 3*, DNA size ladder; *Lanes 5-11*, increasing duration of 17-AAG (100 nM) treatment. (D) Southern blot analysis in 1.5% gel of total minicircles and total maxicircles after digestion of kDNA (ethanol precipitated from lysates) by Avall restriction enzyme (overnight). The blot was


first probed for minicircles (bottom panel), then stripped and reprobed for maxicircles (top panel). *Lane 1*, Avall-cut network marker; *Lane 2*, DNA size ladder; *Lanes 4-8*, increasing duration of 17-AAG (100 nM) treatment. Samples loaded by equal cell equivalents.




Supplementary Figure 4. Densitometry quantification of *HSP83* mRNA and protein from Figure 4, by mean grey values. (A) Time course of mRNA in northern blots from cells induced for RNAi of *HSP83*. *HSP83* (red), tubulin (black), *HSP84* (green), shown relative to time 0 h. (B) *HSP83* (pink) and a cross-reacting protein (50 kDa, black) in western blots from cells induced for *HSP83* RNAi over time, shown relative to uninduced cells, and ratioed to each other (red). Symbols are $M \pm SD$ of three densitometry measurements of the same blot.




Supplementary Figure 5. Southern blot of free minicircles isolated at indicated times from *HSP83* RNAi-induced trypanosomes and separated in ethidium agarose (biological replicate of Fig. 5A to show theta region). *Lane 1*, uninduced cells at t_{0h} ; *Lanes 2 and 3*, increasing hours of RNAi. Lanes loaded by equal cell equivalents. *O*, oligomers of two or more interlocked circles; *T*, theta structures; *N/G*, mature nicked, or gapped daughters; *L*, linears, *N*, immature nicked daughters; *CC*, covalently closed template circles.



Supplementary Figure 6. *Hsp83* RNAi induction does not significantly change the percent of 2N cells with a visibly ingressed cleavage furrow. Merged phase contrast and DAPI fluorescence images of trypanosomes before and after induction of *HSP83* RNAi. $M \pm SD$, $n \geq 3$.



Supplementary Figure 7. Densitometry quantification of mRNA and protein in cells with inducible constructs for RNAi of *HSP84*, by mean grey values (Figure 6 data). (A) mRNA bands of *HSP84*, from uninduced (*black*) or induced (*green*) cells, and of *HSP83* (*red*) in induced cells, by northern blot, shown relative to 0 h. (B) *HSP84*-cmyc (*light green*) and a cross-reacting protein (60 kDa, *black*) bands, and their ratio (*dark green*), by western blot, across time in induced cells (shown relative to uninduced, time 0 h). Symbols are $M \pm SD$ of three densitometry measurements of the same blot.



Supplementary Figure 8. Impact of antitrypanosomal drug isometamidium chloride (Samorin) on free minicircles. African trypanosomes *T. equiperdum* were treated in vitro with 10 μ M isometamidium, and minicircle DNA was isolated and imaged as described previously [2,3]. (A) Southern blot of free minicircles obtained before (*Lane 1*) and at indicated intervals after addition of isometamidium to cell culture (*Lanes 3-4*). (B) Fluorographs to detect incorporation of [³H]thymidine into nascent DNA. *Lanes 1-3*, free minicircles isolated from control cells metabolically labeled for increasing times with [³H]thymidine. *Lanes 4-6*, minicircle DNA from cells treated with 10 μ M isometamidium for 10 min prior to the addition of [³H]thymidine. All samples obtained in the same experiment; lanes loaded by equal cell equivalents. O, Oligomers of two or more interlocked circles; T, theta structures; N/G, mature nicked, and

gapped daughters; *L*, Linears, *N*, immature nicked daughters; *CC*, covalently closed template circles.

References Cited in Supplement

1. Shapiro TA, Klein VA, Englund PT. Drug-promoted cleavage of kinetoplast DNA minicircles: Evidence for type II topoisomerase activity in trypanosome mitochondria. *J Biol Chem.* **1989**;264: 4173-4178.
2. Shapiro TA, Englund PT. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. *Proc Natl Acad Sci U S A.* **1990**;87: 950-954.
doi: 10.1073/pnas.87.3.950
3. Shapiro TA, Showalter AF. In vivo inhibition of trypanosome mitochondrial topoisomerase II: Effects on kinetoplast DNA maxicircles. *Mol Cell Biol.* **1994**;14: 5891-5897.